FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912402341> ?p ?o ?g. }

• W2912402341 endingPage "138" @default.
• W2912402341 startingPage "129" @default.
• W2912402341 abstract "SummaryBackground: Selective acetylcholinesterase (AChE) and dual acetyl- and butyrylcholinesterase inhibitors constitute the only approved agents for the symptomatic treatment of Alzheimer's disease (AD). Donepezil is a specific, reversible inhibitor of AChE, while rivastigmine is a slowly reversible (pseudoirreversible) dual cholinesterase (ChE) inhibitor, with brain-regional specificity for the cerebral cortex and hippocampus. According to the European Marketing Authorisations, the clinical benefit of ChE inhibitors should be reassessed on a regular basis and discontinuation should be considered when evidence of a therapeutic effect is no longer present. However, substantial differences in the pharmacological and pharmacokinetic profiles of the available ChE inhibitors suggest that it may be desirable to switch between ChE inhibitors if patients fail to show efficacy, deteriorate or are unable to tolerate their initially prescribed medication.Design: This open-label, six-month study evaluated the efficacy and safety of rivastigmine in 382 AD patients who had previously failed to benefit from treatment with donepezil (80% due to lack of efficacy, 11% due to tolerability problems, 9% both reasons).Results: At the end of the study, 56.2% of patients were responders to rivastigmine, as assessed using a global function scale (the Clinicians’ Global Impression of Change). Cognitive performance (measured by the Mini-Mental State Examination) and the ability to perform activities of daily living (measured by the Instrumental Activities of Daily Living scale) were improved/stabilised in 48.9% and 57.0% of patients, respectively. Rivastigmine was generally well tolerated, the most common adverse events being nausea and vomiting, consistent with reports from previous clinical studies. The occurrence of side-effects or lack of efficacy with donepezil treatment was not a predictor of similar problems when treated with rivastigmine.Conclusion: Rivastigmine treatment appears to be beneficial in AD patients who have previously failed to benefit from, or were unable to tolerate treatment with, donepezil." @default.
• W2912402341 created "2019-02-21" @default.
• W2912402341 creator A5049484291 @default.
• W2912402341 creator A5057738628 @default.
• W2912402341 creator A5079793569 @default.
• W2912402341 creator A5090814250 @default.
• W2912402341 date "2002-01-01" @default.
• W2912402341 modified "2023-10-10" @default.
• W2912402341 title "Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil" @default.
• W2912402341 cites W1847168837 @default.
• W2912402341 cites W1985528178 @default.
• W2912402341 cites W1986168671 @default.
• W2912402341 cites W1997886955 @default.
• W2912402341 cites W2004530307 @default.
• W2912402341 cites W2054135384 @default.
• W2912402341 cites W2054662854 @default.
• W2912402341 cites W2057679568 @default.
• W2912402341 cites W2064887457 @default.
• W2912402341 cites W2070566742 @default.
• W2912402341 cites W2070883565 @default.
• W2912402341 cites W2081285591 @default.
• W2912402341 cites W2083677744 @default.
• W2912402341 cites W2084399566 @default.
• W2912402341 cites W2093345349 @default.
• W2912402341 cites W2100969363 @default.
• W2912402341 cites W2116249921 @default.
• W2912402341 cites W2117134611 @default.
• W2912402341 cites W2128529067 @default.
• W2912402341 cites W2138135118 @default.
• W2912402341 cites W2145262930 @default.
• W2912402341 cites W2152678792 @default.
• W2912402341 cites W2156220037 @default.
• W2912402341 cites W2166908320 @default.
• W2912402341 cites W2775750683 @default.
• W2912402341 cites W4248367183 @default.
• W2912402341 cites W4292528167 @default.
• W2912402341 cites W961590786 @default.
• W2912402341 doi "https://doi.org/10.1185/030079902125000471" @default.
• W2912402341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12094822" @default.
• W2912402341 hasPublicationYear "2002" @default.
• W2912402341 type Work @default.
• W2912402341 sameAs 2912402341 @default.
• W2912402341 citedByCount "106" @default.
• W2912402341 countsByYear W29124023412012 @default.
• W2912402341 countsByYear W29124023412013 @default.
• W2912402341 countsByYear W29124023412014 @default.
• W2912402341 countsByYear W29124023412015 @default.
• W2912402341 countsByYear W29124023412016 @default.
• W2912402341 countsByYear W29124023412017 @default.
• W2912402341 countsByYear W29124023412018 @default.
• W2912402341 countsByYear W29124023412019 @default.
• W2912402341 countsByYear W29124023412020 @default.
• W2912402341 countsByYear W29124023412021 @default.
• W2912402341 countsByYear W29124023412022 @default.
• W2912402341 countsByYear W29124023412023 @default.
• W2912402341 crossrefType "journal-article" @default.
• W2912402341 hasAuthorship W2912402341A5049484291 @default.
• W2912402341 hasAuthorship W2912402341A5057738628 @default.
• W2912402341 hasAuthorship W2912402341A5079793569 @default.
• W2912402341 hasAuthorship W2912402341A5090814250 @default.
• W2912402341 hasConcept C126322002 @default.
• W2912402341 hasConcept C142724271 @default.
• W2912402341 hasConcept C181199279 @default.
• W2912402341 hasConcept C185592680 @default.
• W2912402341 hasConcept C197934379 @default.
• W2912402341 hasConcept C204787440 @default.
• W2912402341 hasConcept C27081682 @default.
• W2912402341 hasConcept C2776000289 @default.
• W2912402341 hasConcept C2776332859 @default.
• W2912402341 hasConcept C2778375690 @default.
• W2912402341 hasConcept C2778715236 @default.
• W2912402341 hasConcept C2778816929 @default.
• W2912402341 hasConcept C2779059548 @default.
• W2912402341 hasConcept C2779101902 @default.
• W2912402341 hasConcept C2779134260 @default.
• W2912402341 hasConcept C2779483572 @default.
• W2912402341 hasConcept C2780580376 @default.
• W2912402341 hasConcept C2780904820 @default.
• W2912402341 hasConcept C31896038 @default.
• W2912402341 hasConcept C42219234 @default.
• W2912402341 hasConcept C55493867 @default.
• W2912402341 hasConcept C71924100 @default.
• W2912402341 hasConcept C98274493 @default.
• W2912402341 hasConceptScore W2912402341C126322002 @default.
• W2912402341 hasConceptScore W2912402341C142724271 @default.
• W2912402341 hasConceptScore W2912402341C181199279 @default.
• W2912402341 hasConceptScore W2912402341C185592680 @default.
• W2912402341 hasConceptScore W2912402341C197934379 @default.
• W2912402341 hasConceptScore W2912402341C204787440 @default.
• W2912402341 hasConceptScore W2912402341C27081682 @default.
• W2912402341 hasConceptScore W2912402341C2776000289 @default.
• W2912402341 hasConceptScore W2912402341C2776332859 @default.
• W2912402341 hasConceptScore W2912402341C2778375690 @default.
• W2912402341 hasConceptScore W2912402341C2778715236 @default.
• W2912402341 hasConceptScore W2912402341C2778816929 @default.
• W2912402341 hasConceptScore W2912402341C2779059548 @default.
• W2912402341 hasConceptScore W2912402341C2779101902 @default.
• W2912402341 hasConceptScore W2912402341C2779134260 @default.

• next